Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 19.8% in October

Pulmatrix, Inc. (NASDAQ:PULMGet Rating) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 52,500 shares, a decrease of 19.8% from the October 15th total of 65,500 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 94,400 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently raised its stake in Pulmatrix stock. Renaissance Technologies LLC raised its holdings in shares of Pulmatrix, Inc. (NASDAQ:PULMGet Rating) by 7.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,920 shares of the biotechnology company’s stock after purchasing an additional 8,300 shares during the quarter. Renaissance Technologies LLC owned approximately 3.60% of Pulmatrix worth $560,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 44.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Pulmatrix in a research report on Sunday. They set a “hold” rating for the company.

Pulmatrix Stock Performance

PULM opened at $3.80 on Friday. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $4.43. Pulmatrix has a fifty-two week low of $3.16 and a fifty-two week high of $16.84.

About Pulmatrix

(Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Recommended Stories

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.